Imax price target raised to $27 from $25 at Rosenblatt

Rosenblatt raised the firm’s price target on Imax to $27 from $25 and keeps a Buy rating on the shares. Imax outperformed in Q1, which was driven by the company’s "ability to optimize its film slate," the analyst tells investors. Given the film slate for the year and into 2024, along with the growing importance of local language content, Rosenblatt believes this will set the stage for continued strong financial performance.